Novo has recently announced its collaboration with Anthropic, aimed at accelerating the development of new drugs and artificial intelligence-based software. This news came just hours after Ursula von der Leyen, President of the European Commission, spoke about the benefits of artificial intelligence in the healthcare sector.
New Drug Development with Artificial Intelligence
Novo, the Danish pharmaceutical giant, stated that it will utilize Anthropic's AI models and Claude Science technology to advance its research. Novo aims to become the "AI-driven healthcare company" in the world.
Read more: Lawmakers Are Not Ready to Address AI Safety
Dario Amodei, CEO and co-founder of Anthropic, emphasized that the use of advanced AI models could significantly shorten research timelines. He said, "The increasing capabilities of AI have the potential to reduce a century of biological and medical advancements to a decade."
Data Governance and Human Oversight
The released statement highlighted the need for "strong data governance and human oversight." This issue arises amid growing concerns about the potential negative impacts of artificial intelligence on society. In particular, last week, Anthropic announced that scientists attempted to use Claude technology to develop biological weapons.
Today's speech by von der Leyen regarding the use of AI in health, especially in the early detection of breast cancer through AI-supported mammograms, received attention. She also noted that this technology should empower doctors rather than replace them.
Given the rapid growth of AI technologies and related concerns, the collaboration between Novo and Anthropic could be a turning point in innovative solutions for health challenges. This partnership could not only help accelerate the development of treatments but also establish new standards for the use of AI technologies in healthcare.
